Objective: To review the pharmacologic properties, safety profile, and clinical applications of gadopiclenol across pediatric MRI domains, including neuroimaging, body, and musculoskeletal (MSK) imaging. Learning Points: 1.Pharmacologic Profile: Describe gadopiclenol’s high relaxivity and strong kinetic stability, supporting half-dose administration in children. 2.Diagnostic Performance: Compare enhancement patterns across neuro, body, and MSK MRI with those of conventional macrocyclic agents. 3.Specific Findings: -Neuro: Increased sulcal vascular background on post-contrast T1WI, unchanged FLAIR signal. -Body: Clear delineation of solid organ and vascular structures. -MSK: Adequate depiction of synovial, soft tissue, and marrow enhancement. 4.Pitfalls: Highlight physiologic enhancement and anesthesia-related flow effects. 5.Case Examples: Demonstrate typical lesions across neuro (tumor, meningitis), body (liver, kidney, vasculature), and MSK (infection, inflammation, tumor). 6.Teaching Pearl: Standardize protocols to optimize imaging, avoid misinterpretation, and ensure safe use in pediatric practice. Discussion: Gadopiclenol offers a potential for reduced gadolinium dose while maintaining diagnostic confidence. In neuroimaging, it may increase sulcal vascular background, which can mimic leptomeningeal disease. As with other macrocyclic agents, CE-FLAIR remains valuable for distinguishing vascular signal from true enhancement. In body MRI, enhancement patterns are comparable to other approved agents, supporting visualization of abdominal and pelvic structures. In MSK imaging, tissue-to-background contrast enables soft tissue and marrow lesion assessment similar to standard macrocyclic contrast media. Radiologists should recognize common confounders such as physiologic enhancement patterns, timing of acquisition, and anesthesia effects. Emphasizing CE-FLAIR in neuroimaging, understanding organ-specific patterns, and tailoring protocols are key to accurate interpretation and safe integration of gadopiclenol in pediatric MRI. Read More

Meeting name: SPR 2026 Annual Meeting , 2026

Authors: Valencia Sergio, Machado Rivas Fedel, Gee Michael, Jaimes Camilo

Keywords: Contrast Agent, Brain MRI, Body MRI